Rate and predictors of loss to follow-up in HIV care in a low-resource setting: analyzing critical risk periods
Published in Biomedical Research
Why Do Some People Stop HIV Treatment? Understanding the Key Moments
In the global fight against HIV, keeping people engaged in their treatment is crucial. Even though many countries aim to meet ambitious HIV care goals by 2030, a significant challenge remains: helping those who start HIV treatment continue their care and keep their virus under control. A big part of this challenge is what’s known as "loss to follow-up" (LTFU).
What is Loss to Follow-Up (LTFU)?
LTFU happens when someone on HIV treatment misses their medical appointments or stops taking their medication for over 28 days. This is a serious issue, as it can lead to poorer health, increased risk of death, and a higher chance of spreading HIV to others because the virus isn’t being suppressed.
When Do People Stop Treatment?
This study looked at 737 adults who were new to HIV care and identified the times when they were most likely to stop their treatment:
- The First 6 Months Are Critical: About 50% of the people who dropped out of care did so within the first six months. This early period is a high-risk time, with an LTFU rate nine times higher than later periods (13-24 months). People might face challenges like dealing with side effects, struggling to adjust to a new routine, or not yet seeing the benefits of the medication.
- 7-12 Months: A Continued Risk: Even though the risk of dropping out decreases after the first six months, many people still struggle to stick with their treatment during months 7-12. About 30% of those who stopped care did so during this time. Factors like financial difficulties, stigma, or transportation issues can continue to affect them.
- After 12 Months: A More Stable Phase: After a year on treatment, the dropout rate drops significantly. By this time, many patients have adjusted to their routine, seen improvements in their health, and are more committed to their treatment.
What Can We Do About It?
The findings suggest that the first six months of HIV treatment are a make-or-break time. Health programs should focus on providing extra support during this period, such as helping patients manage side effects and offering counseling. Continued support is also important in the following months to help people overcome challenges that might come up later.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
The rise of invasive fungal infections: diagnostics, antifungal stewardship, prophylaxis, and genetics
BMC Infectious Diseases is calling for submissions to our Collection on The rise of invasive fungal infections: diagnostics, antifungal stewardship, prophylaxis, and genetics.
In recent years, the incidence of invasive fungal infections (IFI) has shown a concerning upward trend, presenting a formidable challenge in clinical settings worldwide. This Collection aims to explore multidimensional aspects crucial for understanding and combating these infections. We invite submissions that explore a wide array of topics within the scope of IFI, including but not limited to:
- Diagnostics: advances in fungal diagnostics, including novel biomarkers, imaging modalities, and molecular techniques, are pivotal for timely and accurate identification of fungal pathogens
- Antifungal stewardship: the prudent use of antifungal agents to mitigate resistance and optimize patient outcomes, and strategies for stewardship (including surveillance, guidelines, and therapeutic drug monitoring)
- Antifungal prophylaxis: effective prophylactic measures in high-risk patient populations (examining prophylactic regimens, their efficacy, and impact on patient outcomes)
- Host and pathogen genetics: understanding the genetic factors influencing both host susceptibility and fungal virulence, and research on genetic markers, host-pathogen interactions, and implications for personalized treatment approaches
- Fungal genetics: insights into fungal genome characteristics, evolution, and mechanisms of resistance, and research exploring fungal genetic diversity, adaptation, and transmission dynamics
- Imaging: imaging technologies that contribute significantly to the diagnosis and management of invasive fungal infections, their clinical utility, and integration with diagnostic algorithms
This Collection aims to foster a dialogue among researchers, clinicians, and healthcare providers on the complexities surrounding IFI. This Collection supports and amplifies research related to SDG 3: Good Health & Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Feb 28, 2026
Cutting-edge diagnostics for infectious diseases: emerging technologies and approaches
BMC Infectious Diseases invites submissions for a Collection on Cutting-edge diagnostics for infectious diseases.
The field of diagnostics for infectious diseases is rapidly evolving, driven by the need for timely and accurate detection methods. Traditional diagnostic techniques often fall short in terms of speed and sensitivity, highlighting a pressing need for innovative solutions. Recent advances in technologies such as molecular diagnostics, biosensors, and next-generation sequencing are paving the way for more efficient and reliable testing methodologies. These emerging approaches have the potential to revolutionize the identification of pathogens, enabling faster clinical decision-making and improving patient outcomes.
Addressing the challenges posed by infectious diseases is critical, particularly in an era marked by global health crises and the rise of antimicrobial resistance. The development and implementation of rapid diagnostic tools can facilitate timely interventions, ultimately reducing morbidity and mortality rates. As researchers and healthcare professionals work collaboratively, significant strides have been made in understanding the complexities of infectious diseases. This includes the adaptation of point-of-care testing technologies that bring laboratory capabilities closer to patients, thus enhancing the capacity for early diagnosis and treatment.
If current research trends continue, we may see transformative advancements that integrate artificial intelligence and machine learning into diagnostic processes. Such innovations could lead to the creation of smart diagnostics that not only detect infections with high accuracy but also provide real-time surveillance data. Future technologies may enable rapid identification of emerging pathogens, thus enhancing public health response strategies and mitigating outbreaks before they escalate.
- Advances in molecular diagnostics for infectious diseases
- Innovations in rapid diagnostic testing
- Applications of next-generation sequencing in pathogen detection
- Biosensors for real-time infectious disease monitoring
- Point-of-care testing technologies and their impact
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Jan 31, 2026
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in